YTHDF3–CENPI Signaling in Triple-Negative Breast Cancer
2026-08-21
A 2025 Frontiers in Oncology study identifies the m6A reader YTHDF3 as a TNBC-associated risk factor and links it mechanistically to stabilization and enhanced translation of CENPI mRNA. The findings connect epitranscriptomic RNA regulation with chromosome-segregation biology and provide a rationale for testing the YTHDF3–CENPI axis as a prognostic and therapeutic target.
Liproxstatin-1 HCl: Ferroptosis Assay Strategy
2026-08-20
Liproxstatin-1 HCl is a nanomolar ferroptosis inhibitor for dissecting lipid peroxidation, GPX4 dependence, and organ-injury mechanisms. This guide focuses on assay interpretation, rescue controls, formulation, and translational limitations rather than repeating a standard pathway overview.
Tigecycline in the Plasmid-Resistance Era
2026-08-20
Tigecycline offers translational researchers a mechanistically distinct way to study multidrug-resistant bacteria as carbapenemase genes move through hospital networks. This article connects the glycylcycline antibiotic’s 30S ribosomal activity with plasmid surveillance, CREC validation workflows, MRSA research, and infection-model design while clearly separating evidence from testable hypotheses.
Naftifine HCl in Mechanism-First Assays
2026-08-19
Naftifine HCl is an allylamine antifungal agent that enables mechanism-first studies of fungal sterol disruption. This article connects squalene 2,3-epoxidase biology with the orthogonal assay logic of a landmark WNT/GSK3/β-catenin study, helping researchers design more interpretable antifungal experiments.
Bay 11-7821 in NF-κB Assay Workflows
2026-08-18
Bay 11-7821, also known as BAY 11-7082, is a practical IKK/NF-κB pathway probe for separating inflammatory transcription from apoptosis and proliferation phenotypes. This guide connects dose-controlled cell assays with macrophage HMGB1 research, while emphasizing solubility, timing, and interpretation limits.
Adefovir Workflows for HBV and OAT1 Research
2026-08-18
Build reproducible Adefovir assays for HBV polymerase inhibition, viral replication studies, and OAT1 transporter phenotyping. This workflow separates antiviral exposure from renal-transport measurements while adapting structural-biology quality controls from a DDX3 crystallography study.
Ibrutinib: Mechanism-to-Readout Research Guide
2026-08-17
Ibrutinib (PCI-32765) is a covalent BTK inhibitor for connecting B-cell receptor signaling inhibition with interpretable cellular phenotypes. This guide emphasizes assay architecture, controls, solvent handling, and lessons from an orthogonal disease-model study.
From T7 Transcription to Smarter RNA Delivery
2026-08-17
T7 RNA Polymerase is more than a high-yield transcription reagent: it is the upstream control point for RNA quality, template reproducibility, and translational decision-making. This thought-leadership article connects defined RNA synthesis with recent evidence that LNP trafficking and endosomal escape—not cellular uptake alone—shape functional delivery.
Nintedanib (BIBF 1120) Assay Guide
2026-08-16
A scenario-based guide to using Nintedanib (BIBF 1120), SKU A8252, in cell viability, proliferation, and cytotoxicity experiments. It connects target potency, DMSO handling, assay controls, ATRX-informed interpretation, and practical supplier selection to improve experimental consistency.
Gingerenone A Reverses Sunitinib Resistance in RCC
2026-08-15
The January 2026 study identifies gingerenone A as an inhibitor of LDHA-driven glycolysis in renal cell carcinoma and links this metabolic effect to disruption of HIF-1α/VEGFA/VEGFR2 signaling. Across biochemical, cellular, and animal models, gingerenone A improved sunitinib activity and restored drug responsiveness in resistant RCC models, supporting metabolism-directed combination therapy while leaving important translational questions unresolved.
WP1066 for JAK2/STAT3 Signaling Research
2026-08-15
WP1066 provides a cell-permeable way to interrogate JAK2/STAT3 signaling in cancer cell proliferation, AML models, and macrophage-centered regeneration studies. This guide connects dose–response assays with scaffold-based pathway validation and practical troubleshooting.
Doxorubicin Hydrochloride: Assay Workflows
2026-08-14
Build reproducible cancer cytotoxicity and cardiotoxicity experiments with Doxorubicin hydrochloride, from dose–time matrices to mechanism-focused validation. This workflow connects DNA damage and apoptosis readouts with the emerging ATF4–H2S antioxidant axis.
Arrb2, 6-ketoLCA, and Hepatic IRI
2026-08-14
This study identifies a hepatocyte Arrb2–6-ketoLCA–M2 macrophage axis that limits hepatic ischemia–reperfusion injury. By combining transplant-associated clinical samples, hepatocyte-targeted mouse models, metabolite profiling, and hypoxia–reoxygenation experiments, the work connects hepatocyte signaling with macrophage-mediated inflammatory resolution.
IAM LC vs LEKC for Pulmonary Drug Permeability
2026-08-13
This Journal of Chromatography A study provides a direct comparison of immobilised artificial membrane liquid chromatography and liposome electrokinetic capillary chromatography for modeling drug–membrane partitioning and pulmonary permeability. LEKC more closely reflected apparent lung permeability for the tested compounds, whereas IAM LC offered broader compound coverage, simpler implementation, and stronger suitability for high-throughput screening.
Bacitracin (B1670): Protocol and QC Guide
2026-08-13
Bacitracin (B1670) provides a peptide antibiotic for controlled antibacterial research involving bacterial cell wall and peptidoglycan synthesis. This guide covers solvent selection, storage, assay controls, and troubleshooting; the material is for scientific research only and must not be used for diagnostic or medical applications.
508 records 11/34 page Previous Next First page 上5页 1112131415 下5页 Last page